Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2005
Business Overview: Repligen is a biopharmaceutical company developing novel therapeutics for central nervous system diseases (schizophrenia, anxiety, bipolar disorder). The company funds its R&D through profits from two commercial products: Protein A (used in monoclonal antibody purification) and SecreFlo (a diagnostic aid for pancreatic disorders).
Key Financial Metrics
| Metric | Fiscal 2005 | Fiscal 2004 | Fiscal 2003 |
|---|---|---|---|
| Total Revenue | $9,360,000 | $6,914,000 | $7,772,000 |
| Gross Profit | $5,472,000 | $3,666,000 | $4,292,000 |
| Gross Margin | 58% | 53% | 55% |
| Net Loss | $(2,984,000) | $(9,551,000) | $(4,537,000) |
| Net Loss Per Share | $(0.10) | $(0.32) | $(0.17) |
| Cash & Marketable Securities | $23,841,000 | $24,663,000 | $18,709,000 |
| Working Capital | $15,673,000 | $13,769,000 | $15,602,000 |
| Long-term Obligations | $120,000 | $86,000 | $2,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 35% to $9.36 million, driven primarily by a 42% increase in Protein A sales ($7.13 million) and a 17% increase in SecreFlo sales ($2.19 million).
- Improved Profitability: The net loss narrowed significantly to $2.98 million from $9.55 million in the prior year. This improvement was due to higher product sales, reduced R&D expenses, and the absence of a $2.4 million impairment charge recorded in 2004.
- Operating Expenses: Total operating expenses decreased 29% to $9.63 million. R&D expenses dropped 22% to $5.04 million following the discontinuation of a Phase III autism trial. SG&A expenses remained relatively flat, decreasing slightly to $4.60 million.
- Other Income: The company recorded $750,000 in other income from a legal settlement with Pro-Neuron, Inc., which contributed to the reduced net loss.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D expenses in fiscal 2006 to remain consistent with fiscal 2005 levels unless a new product candidate is acquired. Current cash balances are deemed adequate to meet needs for at least the next 24 months.
- Commercial Strategy: Repligen aims to use profits from Protein A and SecreFlo to fund neuropsychiatric drug development while minimizing operating losses. An amended supply agreement with GE Healthcare extends through 2010, securing a major revenue stream.
- Legal Contingencies:
- ChiRhoClin Settlement: A settlement was reached regarding the SecreFlo supplier. Repligen will receive $750,000 and is relieved of approximately $1.17 million in accrued royalties (to be recorded as income in Q1 2006). SecreFlo sales will continue until existing supplies are depleted.
- ImClone Litigation: Repligen and MIT are suing ImClone for patent infringement regarding the drug Erbitux, seeking royalties.
- Risks: The company relies on a single supplier for SecreFlo, has limited manufacturing capabilities for pharmaceuticals, and faces significant uncertainty regarding the success of clinical trials for its pipeline products.
Key Facts for Investor Verification
- Revenue Concentration: Customer A (GE Healthcare) accounted for 54% of total revenue in 2005. Customer concentration remains a significant risk.
- SecreFlo Supply Chain: Verify the timeline for the depletion of SecreFlo inventory, as the company will cease marketing the product once supplies from the ChiRhoClin settlement are exhausted.
- Cash Burn Rate: While cash reserves are strong ($23.8 million), the company continues to operate at a loss. Verify the runway for R&D funding if commercial product sales stagnate.
- Patent Litigation: Monitor the status of the ImClone lawsuit and the potential for royalty revenue, as well as the opposition filed by Bristol-Myers Squibb against Repligen's European CTLA4-Ig patent.
- Upcoming Income Recognition: Confirm the recording of the $1.17 million royalty relief from ChiRhoClin in the first quarter of fiscal 2006.